Literature DB >> 17499884

Characterization of Japanese-American men with a single neocortical AD lesion type.

Helen Petrovitch1, G Webster Ross, Qimei He, Jane Uyehara-Lock, William Markesbery, Daron Davis, James Nelson, Kamal Masaki, Lenore Launer, Lon R White.   

Abstract

Neocortical neuritic plaques (NP) and neurofibrillary tangles (NFT) are hallmarks of Alzheimer's disease (AD) and usually, both are present. The Honolulu-Asia Aging Study autopsy series includes a significant number of individuals with only one neocortical AD lesion type. These could represent an early phase of the AD process. If so, such individuals would be expected to share other clinical and pathological features of AD. We compared frequency of apolipoprotein epsilon E4 (APOE4) allele, average Braak stage, and burden of cerebral amyloid angiopathy (CAA) among the two single lesion type groups, a group without AD lesions, and groups with high and low frequencies of both AD lesions. Single AD lesion groups shared only the characteristics associated with their unique lesion type with the combined AD lesion group and did not have higher prevalence of dementia than the no AD lesion group. Only the NP+NFT group showed a "dose-response" relationship with greater probability of dementia with higher neocortical frequencies of either AD lesion. The single neocortical AD lesion groups do not appear to represent early AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499884      PMCID: PMC2613368          DOI: 10.1016/j.neurobiolaging.2007.03.026

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  45 in total

1.  Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study.

Authors:  H Petrovitch; L R White; G W Ross; S C Steinhorn; C Y Li; K H Masaki; D G Davis; J Nelson; J Hardman; J D Curb; P L Blanchette; L J Launer; K Yano; W R Markesbery
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

Review 2.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.

Authors:  J C Morris; J L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

3.  Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants.

Authors:  Lon White; Helen Petrovitch; John Hardman; James Nelson; Daron G Davis; G Webster Ross; Kamal Masaki; Lenore Launer; William R Markesbery
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

4.  Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study.

Authors:  Michiko Yamada; Fumiyoshi Kasagi; Hideo Sasaki; Naomi Masunari; Yasuyo Mimori; Gen Suzuki
Journal:  J Am Geriatr Soc       Date:  2003-03       Impact factor: 5.562

5.  APOE-epsilon4 predicts incident AD in Japanese-American men: the honolulu-asia aging study.

Authors:  R J Havlik; G Izmirlian; H Petrovitch; G W Ross; K Masaki; J D Curb; A M Saunders; D J Foley; D Brock; L J Launer; L White
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

6.  Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease.

Authors:  Thomas W Mitchell; Elliott J Mufson; Julie A Schneider; Elizabeth J Cochran; Jonathan Nissanov; Li-Ying Han; Julia L Bienias; Virginia M -Y Lee; John Q Trojanowski; David A Bennett; Steven E Arnold
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

7.  Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study.

Authors:  L A Pfeifer; L R White; G W Ross; H Petrovitch; L J Launer
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

8.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; William R Markesbery
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

9.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

Authors:  Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

10.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.

Authors:  Ian G McKeith
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

View more
  14 in total

Review 1.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

2.  Modeling regional vulnerability to Alzheimer pathology.

Authors:  Donald R Royall; Raymond F Palmer; Helen Petrovitch; G Webster Ross; Kamal Masaki; Lon R White
Journal:  Neurobiol Aging       Date:  2011-07-30       Impact factor: 4.673

3.  The Honolulu-Asia Aging Study: epidemiologic and neuropathologic research on cognitive impairment.

Authors:  Rebecca P Gelber; Lenore J Launer; Lon R White
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

4.  The temporospatial evolution of neuritic plaque-related and independent tauopathies: implications for dementia staging.

Authors:  Donald R Royall; Raymond F Palmer
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 5.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

Review 6.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

Review 7.  Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2.

Authors:  Sudha Seshadri; Alexa Beiser; Rhoda Au; Philip A Wolf; Denis A Evans; Robert S Wilson; Ronald C Petersen; David S Knopman; Walter A Rocca; Claudia H Kawas; Maria M Corrada; Brenda L Plassman; Kenneth M Langa; Helena C Chui
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

8.  Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression.

Authors:  Tina L Beckett; Robin L Webb; Dana M Niedowicz; Christopher J Holler; Sergey Matveev; Irfan Baig; Harry LeVine; Jeffrey N Keller; M Paul Murphy
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 9.  Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship.

Authors:  Peter T Nelson; Heiko Braak; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2009-01       Impact factor: 3.685

10.  Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons.

Authors:  Peter T Nelson; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Charles D Smith; Daron G Davis; John W Poduska; Ela Patel; Marta S Mendiondo; William R Markesbery
Journal:  Brain Pathol       Date:  2008-11-19       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.